Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384839 · ClinicalTrials.gov registry record · Phase 2
Vidaza to Restore Hormone Thx Prostate
A Phase 2 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00384839 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 36 participants.
The verdict
NCT00384839, a Phase 2 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a bone marrow disease. The pharmaceutical company involved in this study, Pharmion Corporation, is the manufacturer of Vidaza.
Interventions
- DRUG azacitidine for injectable suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384839
The ClinicalTrials.gov registry entry for NCT00384839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which azacitidine for injectable suspension is the first listed.
NCT00384839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384839 about?
NCT00384839 is a clinical study titled "Vidaza to Restore Hormone Thx Prostate". The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a...
What is the current status of trial NCT00384839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2006-04. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00384839?
The interventions under investigation include: azacitidine for injectable suspension (DRUG).
Who is sponsoring clinical trial NCT00384839?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.